The Neural Tourniquet: A Tiny Device Aims to Stop Bleeding with Electricity

DALLAS, TX – July 13, 2026 – In the relentless race against time to stop severe bleeding, the tools have long been familiar: pressure, packing, and pharmaceuticals. But a groundbreaking first-in-human study suggests a radically different approach, one that looks less like a trauma kit and more like a high-tech earbud. Dallas-based Spark Biomedical, in partnership with Northwell Health’s Feinstein Institutes for Medical Research, has published evidence that a small, non-invasive device that stimulates nerves in the ear can safely enhance the body's own ability to form blood clots.

The research, published in the peer-reviewed journal Bioelectronic Medicine, provides the first clinical proof that transcutaneous auricular neurostimulation (tAN®) can effectively prime platelets for action. This “neural tourniquet” concept marks a significant milestone in the burgeoning field of bioelectronic medicine, which seeks to treat diseases and injuries by speaking the body’s native electrical language. For the millions affected by trauma, complex surgeries, or bleeding disorders, it signals a potential future where controlling hemorrhage is as simple as flipping a switch.

The Science of a Neural Switch

At the heart of the innovation is a wearable platform that delivers gentle electrical pulses to the ear, targeting branches of the vagus and trigeminal nerves. This isn't a brute-force electrical shock; it's a precisely calibrated signal designed to tap into the nervous system's command-and-control functions over the body's physiology.

"This study marks an important milestone for bioelectronic medicine," said Navid Khodaparast, PhD, Chief Science Officer and Co-founder of Spark Biomedical. "For the first time, we have shown that Spark's core tAN® technology can modulate neural circuits to enhance platelet readiness in humans."

The study explored the underlying mechanisms, building on years of preclinical research. Stimulating the vagus nerve, a critical information highway connecting the brain to the body's organs, was found to trigger a sophisticated biological cascade. The nerve signal travels to the spleen, prompting specific immune cells (T lymphocytes) to release acetylcholine. This chemical messenger then interacts with receptors on circulating platelets, increasing their internal calcium levels. This process doesn't create clots out of thin air; rather, it “primes” the platelets, making them hyper-responsive and ready to aggregate more quickly and effectively at the site of an injury.

Simultaneously, stimulating the trigeminal nerve appears to help stabilize the body during hemorrhagic shock by balancing the sympathetic (“fight-or-flight”) and parasympathetic (“rest-and-digest”) nervous systems. The combined effect, demonstrated in this initial human trial, was an increase in platelet function and an accelerated clotting process, all without dangerous systemic side effects. Crucially, researchers reported no adverse events and no signs of hypercoagulability—the formation of unwanted blood clots—which is a major risk with many traditional hemostatic drugs.

"Spark's wearable platform offers a portable, non-invasive approach that could one day be used in trauma settings, operating rooms, and for patients with bleeding disorders," explained Jared M. Huston, MD, the lead investigator and a professor at the Feinstein Institutes, a global leader in bioelectronic medicine research. "This research strengthens the scientific foundation for using targeted neurostimulation to help the body control hemorrhage."

From the Battlefield to the Delivery Room

The potential applications for such a device are vast and life-altering. Uncontrolled bleeding is a leading cause of preventable death in trauma, a grim reality for soldiers on the battlefield and victims of civilian accidents alike. A portable, easy-to-apply device could be a standard-issue tool for first responders, buying critical time for patients en route to a hospital.

Inside the hospital, the technology could transform patient management. In the operating room, surgeons could proactively enhance a patient's clotting ability before a high-risk procedure, potentially reducing the need for blood transfusions. For the nearly 140,000 women worldwide who die annually from postpartum hemorrhage, a rapid, non-pharmacologic intervention could be a lifesaver.

Perhaps most profoundly, it offers new hope for those living with chronic bleeding disorders. Spark Biomedical has already targeted von Willebrand disease—the most common inherited clotting disorder—through its subsidiary, Five Liters. For these patients, a minor injury can become a major medical event. A wearable device that bolsters their body's natural clotting response on demand could drastically improve their quality of life and reduce their reliance on frequent, expensive infusions of clotting factors.

Charting the Path to Market

While the science is promising, the journey from a landmark study to a widely available medical tool is a long one, paved with regulatory hurdles and commercial challenges. However, Spark Biomedical is not a newcomer to this process. The company has already successfully brought a wearable neurostimulation product, Sparrow Ascent, through FDA clearance for the relief of opioid withdrawal symptoms. This experience provides them with a valuable roadmap for navigating the complex regulatory landscape.

The Neural Tourniquet™ will likely be classified as a Class II or Class III medical device, requiring extensive further clinical trials to prove its safety and efficacy in actual bleeding patients, not just healthy volunteers. The company has already demonstrated a robust commitment to clinical development, with numerous trials underway across its three strategic pillars: Neurohealth, Hemostasis, and Autoimmune & Inflammation.

"This publication further validates the broad therapeutic potential of our tAN® platform," noted Anja Krammer, Chief Executive Officer of Spark Biomedical. She sees the findings as opening "exciting new frontiers beyond behavioral health" and identifying new ways to use neuromodulation to influence the nervous and immune systems.

A Landmark Study with Hurdles Ahead

As with any first-in-human study, this research has its limitations. The trial was conducted on a small number of healthy subjects, whose physiological response may differ significantly from that of a patient in traumatic shock or with a congenital coagulopathy. The true test will come in larger, more diverse clinical trials designed to measure real-world outcomes, such as reduced blood loss and improved survival rates.

The researchers themselves are clear-eyed about the path forward, concluding that the technology warrants significant additional study for traumatic hemorrhage, surgical bleeding, and bleeding disorders. Yet, the initial findings represent a fundamental shift in our thinking about hemostasis. For centuries, we have treated bleeding from the outside in. By tapping into the body's own neural wiring, bioelectronic medicine is pioneering a new paradigm—one that works from the inside out.